Effectiveness of ranibizumab and aflibercept in branch retinal vein occlusion
Retina-Vitreus, cilt.29, sa.3, ss.232-237, 2020 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 29 Sayı: 3
- Basım Tarihi: 2020
- Doi Numarası: 10.37845/ret.vit.2020.29.41
- Dergi Adı: Retina-Vitreus
- Derginin Tarandığı İndeksler: Scopus, Academic Search Premier, EMBASE, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.232-237
- Anahtar Kelimeler: Aflibercept, Branch retinal vein occlusion, Macular edema, Ranibizumab
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Purpose: To assess functional and anatomic effectiveness of intravitreal ranibizumab and aflibercept injection given to patients with macular edema secondary to branch retinal vein occlusion. Method: We retrospectively reviewed files of 62 treatment-naive patients with macular edema due to branch retinal vein occlusion. The best-corrected visual acuity and optic coherence parameters were recorded on months 0, 1, 3, 6 and 12 in all patients. First 3 injections were performed in a monthly manner. Pro re nata (PRN) regimen was given during follow-up. Findings: Baseline visual acuity was 50.7±7.6 letters in ranibizumab group and 49.2±6.7 letters in aflibercept group (p=0.403). No significant difference was detected in visual acuity on month 12 between groups (p=0.313). Again, no significant difference was detected in central foveal thickness on month 12 between groups (p=0.408). Mean number of intravitreal injection was 6.2±1.4 in ranibizumab group and 5.7±1.0 in aflibercept group (p=0.174). At the end of month 12, complete recovery in subretinal detachment was detected in 16 patients (88.8%) receiving ranibizumab and 15 patients receiving aflibercept (93.8%) (p=0.525). Conclusion: In our study, no significant difference was detected in reduction of central foveal thickness, improvement in visual acuity and number of injections between two agents.